2023
End-of-Life Systemic Oncologic Treatment in the Immunotherapy Era: The Role of Race, Insurance, and Practice Setting
Canavan M, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Adelson K. End-of-Life Systemic Oncologic Treatment in the Immunotherapy Era: The Role of Race, Insurance, and Practice Setting. Journal Of Clinical Oncology 2023, 41: 4729-4738. PMID: 37339389, PMCID: PMC10602547, DOI: 10.1200/jco.22.02180.Peer-Reviewed Original ResearchConceptsSystemic treatmentEnd of lifeWhite patientsBlack patientsOdds ratioLarge real-world populationPractice settingsTreatment ratesPatient-level factorsEmergency department useIntensive care unitReal-world populationDay of deathImmunotherapy eraSystemic therapyOncologic treatmentCare unitDeidentified databaseDepartment usePatient raceInsurance typeMetastatic cancerDownstream careMedicaid patientsHigher odds
2020
The association between Medicare’s next generation sequencing (NGS), national coverage decision (NCD), and NGS utilization.
Wong W, Sheinson D, Ogale S, Flores C, Gross C. The association between Medicare’s next generation sequencing (NGS), national coverage decision (NCD), and NGS utilization. Journal Of Clinical Oncology 2020, 38: 98-98. DOI: 10.1200/jco.2020.38.29_suppl.98.Peer-Reviewed Original ResearchMetastatic breast cancerMetastatic colorectal cancerAdvanced non-small cell lung cancerNational coverage decisionNGS testingUtilization trendsNext-generation sequencingNGS testsNon-small cell lung cancerCell lung cancerInterrupted time series analysisDe-identified databaseDiagnosis dateAdvanced melanomaPrimary cancerRetrospective studyColorectal cancerLung cancerInsurance typeCancer clinicMetastatic cancerBreast cancerUse of NGSTesting ratesCancer